New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
10:43 EDTACHN, ATML, HLT, MTGE, AVNR, PPG, CLSN, OREX, END, AMKRHigh option volume stocks
High option volume stocks: CLSN HLT AMKR PPG ATML END AVNR ACHN OREX MTGE
News For CLSN;HLT;AMKR;PPG;ATML;END;AVNR;ACHN;OREX;MTGE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 28, 2014
08:13 EDTAVNRAvanir CRL news for AVP-825 as expected, says JMP Securities
Subscribe for More Information
06:07 EDTACHNStocks with implied volatility above IV index mean; DG ACHN
Subscribe for More Information
November 26, 2014
16:57 EDTAVNRAvanir receives CRL from FDA on AVP-825
Subscribe for More Information
13:35 EDTACHNAchillion volatility elevated
Subscribe for More Information
13:25 EDTACHNAchillion to benefit from Bristol-Myers CRL, says FBR Capital
FBR Capital expects Achillion (ACHN) to benefit from the complete response letter that the FDA sent to Bristol-Myers (BMY) on its daclatasvir HCV drug. The firm thunks the letter increases the value of GT-3 HCV patients for Achillion. FBR says that GT-3 patients constitute 5% of HCV patients in the U.S. and significantly higher in Europe. It keeps an Outperform rating on Achillion.
13:11 EDTACHNAchillion mentioned positively at FBR Capital
07:48 EDTAVNRFDA PDUFA Date for Avanir's AVP-825 is November 26, 2014
Subscribe for More Information
07:02 EDTAMKRTessera arbitration award against Amkor upheld by appellate court
Subscribe for More Information
06:07 EDTACHNStocks with implied volatility above IV index mean; DG ACHN
Subscribe for More Information
November 24, 2014
10:32 EDTAVNRDoctors viewing Avanir AVP-923 data favorably, says Deutsche Bank
Subscribe for More Information
November 21, 2014
09:17 EDTOREXOn The Fly: Pre-market Movers
Subscribe for More Information
08:10 EDTOREXOrexigen announces allowance of new U.S. patent for Contrave
Orexigen Therapeutics announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 11/757,773, which covers use of Orexigen's sustained release formulation of naltrexone, which was designed to improve drug tolerability for Contrave in a method for treating obesity. The patent is expected to expire in March of 2028. Orexigen expects the patent to be listed in the Orange Book maintained by the FDA.
07:27 EDTATMLNeedham to hold a tour
Needham Tech Tour travels throughout Silicon Valley on November 20-21.
November 19, 2014
09:21 EDTHLTHilton working with Jones Lang LaSalle on sale of Sydney hotel, Bloomberg says
Subscribe for More Information
05:44 EDTACHNStocks with implied volatility movement; MCD KO
Subscribe for More Information
November 18, 2014
07:29 EDTHLTDeutsche Bank to hold a conference
Subscribe for More Information
November 17, 2014
09:31 EDTAMKRAmkor Technology upgraded to Buy from Neutral at Sidoti
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use